ROBERT HAMILTON: Open Payments
NPI 1619412012 · HARRIS, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,581 in 162 payments from 15 companies in 2025. Trend: 2023 $648 · 2024 $2,188 · 2025 $2,581
Food & beverage: $2,581
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 86 | $1,147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $449 |
| Supernus Pharmaceuticals, Inc. | 11 | $219 |
| Otsuka America Pharmaceutical, Inc. | 17 | $181 |
| Teva Pharmaceuticals USA, Inc. | 5 | $124 |
| Neurocrine BioSciences, Inc. | 3 | $86 |
| Alkermes, Inc. | 3 | $78 |
| Janssen Pharmaceuticals, Inc | 2 | $56 |
| Lundbeck LLC | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $46 |
Products named: VRAYLAR, CAPLYTA, Qelbree, REXULTI, AUSTEDO XR, INGREZZA, SPRAVATO, LYBALVI.
Industry payments across NY — which companies pay providers there.
